Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee
Links shared publicly online about this topic.
- 1,121total visits
Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee
MedImmune today announced that the U.S. Food and Drug Administration's Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus disease in high-risk infants.
View full resource at news-medical.net
Tags: Sore Throat, Respiratory Syncytial Virus, Disease and Condition, Drug, Children's Health, FDA, Oncology
Most Recently Shared on June 3, 2010 at 11:22 am By:
Oncology News: Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee: MedImmune... http://bit.ly/94IVYB
FDA Advisory Committee Reviews MedImmune's Motavizumab
medicalnewstoday.com — “MedImmune announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regar” View full resource at medicalnewstoday.com
Most Recently Shared on June 3, 2010 at 1:13 pm By:
MNT Pharma News Pharma and Health News
FDA Advisory Committee Reviews MedImmune's Motavizumab http://mnt.to/3DrN #pharma #pharmaceutical
Advertisement
